跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TAKHZYRO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TAKHZYRO
Authorized
STANDARD
TAKHZYRO
takeda canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ee96e9e56f6e9b30
Company
takeda canada inc
Type
Standard
Approval Details
Approval Id
ee96e9e56f6e9b30
Drug Approval Canada Name
TAKHZYRO
Product Name
TAKHZYRO
Status
Marketed
Status Date
2022-02-28
Original Market Date
2021-01-18
Din
02505614
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
92:32.00
Atc Original
B06AC05 LANADELUMAB
Atc Name
b 06 ac 05
Aig Number
0160670001
Company Name
takeda canada inc
Company Address
3800, 22 Adelaide Street West, Toronto, Ontario, Canada, M5H 4E3
Active Ingredients
LANADELUMAB
300 MG / 2 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ee96e9e56f6e9b30
Type
Standard
Back to Health Canada Approvals